Butyrate restores motile function and actin cytoskeletal network integrity in Apc mutated mouse colon epithelial cells

Nutrition and Cancer

Volumn 45, Issue 1, 2003, Pages 84-92

  Forest, Virginie ^a   Clément, Monique ^a   Pierre, Fabrice ^a   Meflah, Khaled ^a   Menanteau, Jean ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; BUTYRIC ACID;

ACTIN CYTOSKELETON; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOHYDRATE METABOLISM; CARCINOGENESIS; CELL LINE; CELL MIGRATION; CELL MOTILITY; COLON FLORA; COLON MUCOSA; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOSKELETON; DIET; FERMENTATION; GENE MUTATION; INTESTINE EPITHELIUM CELL; MOUSE; MOUSE STRAIN; NONHUMAN; TUMOR SUPPRESSOR GENE;

ANIMALIA;

EID: 0037633001     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/S15327914NC4501_10     Document Type: Article

References (34)

1. Powell SM, Zilz N, Beazer-Barcley Y, Bryan TM, Hamilton SR, et al.: APC mutations occurs early during colorectal carcinogenesis. Nature (Lond) 359, 235-239, 2001.
2. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, et al.: Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275, 1787-1790, 1997.
3. Hülsken J, Birchmeier W, and Behrens J: E-cadherin and APC compete for the interaction with β-catenin and the cytoskeleton. J Cell Biol 127, 2061-2069, 1994.
4. Näthke IS, Adams CL, Polakis P, Selli JH, and Nelson WJ: The adenomatous polyposis coli tumor suppressor protein localizes to plasma membrane sites involved in active cell migration. J Cell Biol 134, 165-179, 1996.
5. Wong MH, Hermiston ML, Syder AJ, and Gordon JI: Forced expression of the tumor suppressor adenomatosis polyposis coli protein induces disordered cell migration in the intestinal epithelium. Proc Natl Acad Sci USA 93, 9588-9593, 1996.
6. Mahmoud NN, Boolbo SK, Bilinski RT, Martucci C, and Chadburn A: Apc gene mutation is associated with a dominant-negative effect upon intestinal cell migration. Cancer Res 57, 5045-5050, 1997.
7. Mahmoud NN, Bilinski RT, Churchill MR, Edelman W, Kucherlapati R, et al.: Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration in response to sulindac. Cancer Res 59, 353-359, 1999.
8. Kawasaki Y, Senda T, Ishidate T, Koyama R, Morishita T, et al.: Asef, a link between the tumor suppressor APC and G-protein signaling. Science 289, 1194-1197, 2000.
9. Wilson AJ and Gibson PR: Short-chain fatty acids promote the migration of colonic epithelial cells in vitro. Gastroenterology 113, 487-496, 1997.
10. Mariadason JM, Velcich A, Wilson AJ, Augenlicht LH, and Gibson PR: Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation. Gastroenterology 120, 889-899, 2001.
11. McIntyre A, Gibson PR, and Young GP: Butyrate production from dietary fibre and protection against large bowel cancer in a rat model. Gut 34, 386-391, 1993.
12. Perrin P, Pierre F, Patry Y, Champ M, Berreur M, et al.: Only fibers promoting a stable butyrate-producing colonic ecosystem decrease the rate of aberrant crypt foci in rats. Gut 48, 53-61, 2001.
13. Jat PS, Noble MD, Ataliotis P, Tanaka Y, Yannoutsos N, et al.: Direct derivation of conditionally immortal cell lines from an H-2Kb-tsA58 transgenic mouse. Proc Natl Acad Sci USA 88, 5096-5100, 1991.
14. Albrecht-Buehler G: The phagokinetic tracks of 3T3. Cell, 11, 395-404, 1977.
15. Whitehead RH and Joseph JL: Derivation of conditionally immortalized cell lines containing the Min mutation from the normal colonic mucosa and other tissues of an "Immortomouse"/Min hybrid. Epithelial Cell Biol 3, 119-125, 1994.
16. Small IV, Rottner K, Hahne P, and Anderson KI: Visualising the actin cytoskeleton. Microsc Res Tech 47, 3-13, 1999.
17. Friederich E, Vancompernolle K, Louvard D, and Vandekerckhove J: Villin function in the organization of the actin cytoskeleton. J Biol Chem 274, 26751-26760, 1999.
18. Shih IM, Wang TL, Traverso G, Romans K, Hamilton SR, et al.: Top-down morphogenesis of colorectal tumors. Proc Natl Acad Sci USA 98, 2640-2645, 2001.
19. Kruh J: Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 42, 65-82, 1982.
20. Le Blay G, Blottière HM, Ferrier L, Le Foll E, Bonnet C, et al.: Short-chain fatty acids induce cytoskeletal and extracellular protein modifications associated with modulation of proliferation on primary culture of rat intestinal smooth muscle cells. Digest Dis Sci 45, 1623-1630, 2000.
21. Bordonaro M, Mariadason JM, Aslam F, Heerdt BG, and Augenlicht LH: Butyrate-induced apoptotic cascade in colonic carcinoma cells: modulation of the β-catenin-Tcf pathway and concordance with effects of sulindac and trichostatin A but not curcumin. Cell Growth Differ 10, 713-720, 1999.
22. Bordonaro M, Lazarova DL, Augenlicht LH, and Sartorelli AC: Cell type-and promotor-dependent modulation of the Wnt signaling pathway by sodium butyrate. Int J Cancer 97, 42-51, 2002.
23. Clausen MR: Production and oxidation of short-chain fatty acids in the human colon. Dan Med Bull 45, 51-75, 1998.
24. Singh B, Halestrap AP, and Paraskeva C: Butyrate can act as a stimulator of growth or inducer of apoptosis in human colonic epithelial cell lines depending on the presence of alternative energy sources. Carcinogenesis 18, 1265-1270, 1997.
25. Hague A, Singh B, and Paraskeva C: Butyrate acts as a survival factor for colonic epithelial cells: further fuel for the in vivo versus in vitro debate. Gastroenterology 112, 1036-1040, 1997.
26. Lambert DW, Wood IS, Ellis A, and Shirazi-Beechey SP: Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. Br J Cancer 86, 1262-1269, 2002.
27. Augenlicht LH, Anthony GM, Church TL, Edelman W, Kucherlapati R, et al.: Short-chain fatty acid metabolism, apoptosis, and Apc-initiated tumorigenesis in the mouse gastrointestinal mucosa. Cancer Res 59, 6005-6009, 1999.
28. Segal I, Edwards CA, and Walker ARP: Continuing low colon cancer incidence in African populations. Am J Gastroenterol 95, 859-860, 2000.
29. Boffa LC, Vidali G, and Mann RS: Suppression of histone acetylation in vivo and in vitro by sodium butyrate. J Biol Chem 253, 3364-3366, 1978.
30. Vidali G, Boffa LC, and Bradbury EM: Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associated DNA sequences. Proc Natl Acad Sci USA 75, 2239-2243, 1978.
31. Leng SL, Leeding KS, Gibson PS, and Bach LA: Insulin-like growth factor-II renders L1M 2405 human colon cancer cells resistant to butyrate-induced apoptosis: a potential mechanism for colon cancer cell survival in vivo. Carcinogenesis 22, 1625-1631, 2001.
32. Strahl BD and Allis CD: The language of covalent histone modifications. Nature 403, 41-45, 2000.
33. Schmitz S, Clayton J, Nongthomba U, Prinz H, Veigel C, et al.: Drosophila ACT88F indirect flight muscle-specific actin is not N-terminally acetylated: a mutation in N-terminal processing affects actin function. J Mol Biol 295, 1201-1210, 2000.
34. Tsukamoto A, Kaneko Y, and Kurokawa K: Increased assembly of cytoskeletal proteins associated with the transformation of human liver cells into fibroblast-like cells. Experientia 48, 495-497, 1992.